SCHEDULE 13G: Goldman Sachs Discloses 7.4% Passive Stake in Fate Therapeutics
Schedule 13G Filing
The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have disclosed a passive beneficial ownership of 7.4% in Fate Therapeutics, Inc. common stock.
Summary
- The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC jointly filed a Schedule 13G, indicating beneficial ownership in FATE THERAPEUTICS, INC.
- As of March 31, 2025, the reporting persons collectively beneficially own 8,487,220.38 shares of Fate Therapeutics' common stock.
- This aggregate amount represents 7.4% of the total outstanding common stock of Fate Therapeutics.
- The filing indicates that the shares are held with shared voting power of 8,486,823.38 shares and shared dispositive power of 8,487,220.38 shares.
- Neither reporting person holds sole voting power nor sole dispositive power over any shares.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of passive ownership, providing no direct positive or negative sentiment regarding the issuer's performance or outlook. It is a neutral regulatory filing.
Future Outlook
NA
Industry Context
This Schedule 13G filing is a routine disclosure required when an institutional investor acquires beneficial ownership of more than 5% of a company's voting class of securities, and holds them passively. It indicates that Goldman Sachs views its stake in Fate Therapeutics as a passive investment, not intended to influence or change control of the company. Such filings provide transparency into significant institutional holdings in publicly traded companies.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's passive stake, which may be viewed as a vote of confidence in the company's long-term prospects by a major financial institution.
Key Dates
| Date | Description |
|---|---|
| 2023-12-01 | Previous Power of Attorney granted by Goldman Sachs & Co. LLC was superseded. |
| 2024-02-09 | Previous Power of Attorney granted by The Goldman Sachs Group, Inc. was superseded. |
| 2024-07-29 | Date of new Power of Attorney for The Goldman Sachs Group, Inc., effective until July 29, 2025. |
| 2024-10-01 | Date of new Power of Attorney for Goldman Sachs & Co. LLC, effective until October 1, 2025. |
| 2025-03-31 | Date of event which requires the filing of this Schedule 13G statement. |
| 2025-04-02 | Date of filing of the Schedule 13G statement. |
Keywords
Goldman Sachs, Fate Therapeutics, Schedule 13G, Beneficial Ownership, Institutional Ownership, Common Stock, SEC Filing, Investment, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.